MIRM Q3 2023 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+154.1% YoY

Gross Profit

$37M78.6% margin

Operating Income

-$25M-52.7% margin

Net Income

-$24M-49.4% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+27.3%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$651M

Total Liabilities

$382M

Stockholders' Equity

$269M

Cash & Equivalents

$303M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$19M	+154.1%
Gross Profit	$37M	$16M	+136.6%
Operating Income	-$25M	-$33M	+23.5%
Net Income	-$24M	-$36M	+33.9%

Revenue Segments

Product

$48M86%

License Revenue

$8M14%